Technical Analysis for SCYX - SCYNEXIS, Inc.

Grade Last Price % Change Price Change
F 1.34 -1.84% -0.03
SCYX closed down 1.84 percent on Friday, November 1, 2024, on 67 percent of normal volume. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- so don't be surprised if it goes sideways or bounces.
Earnings due: Nov 11
*** please verify all earnings dates ***
2 Watchers
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Down Down Down

Date Alert Name Type % Chg
Lower Bollinger Band Walk Weakness 0.00%
Below Lower BB Weakness 0.00%
Lower Bollinger Band Touch Weakness 0.00%
Oversold Stochastic Weakness 0.00%
Narrow Range Bar Range Contraction -1.84%
Lower Bollinger Band Walk Weakness -1.84%
Inside Day Range Contraction -1.84%
BB Squeeze Ended Range Expansion -1.84%
Lower Bollinger Band Touch Weakness -1.84%
Oversold Stochastic Weakness -1.84%

   Recent Intraday Alerts

Alert Time
Down 2 % about 19 hours ago
Possible NR7 about 19 hours ago
60 Minute Opening Range Breakdown about 21 hours ago
Fell Below Lower Bollinger Band about 21 hours ago
Down 1% about 21 hours ago

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

SCYNEXIS, Inc. Description

SCYNEXIS, Inc., a pharmaceutical company, is engaged in the discovery, development, and commercialization of anti-infectives to address unmet therapeutic needs. It is developing its lead product candidate, SCY-078, as an oral and intravenous (IV) drug, which has completed Phase I clinical trials for the treatment of serious and life-threatening invasive fungal infections in humans against a range of Candida and Aspergillus fungal species, including drug resistant strains. The company, through its proprietary platform for cyclophilin inhibitors, is also developing clinical stage compounds, including SCY-635, an orally available cyclophilin inhibitor that has demonstrated clinical activity against Hepatitis C virus as a single agent and when dosed in combination with pegylated interferon and ribavirin; and SCY-641, a cyclophilin inhibitor with activity similar to cyclosporine, the active ingredient in Restasis and Optimmune drugs currently approved for dry eye disease in humans and dogs, respectively. In addition, it provides contract research and development services. The company was formerly known as SCYNEXIS Chemistry & Automation, Inc. and changed its name to SCYNEXIS, Inc. in June 2002. SCYNEXIS, Inc. was founded in 1999 and is headquartered in Durham, North Carolina.


Classification

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Keywords: Medicine Pharmaceutical Drugs Eye Medication Dog Hepatitis C Eye Diseases Hepatitis C Virus Interferon Anti Infectives Dry Eye Disease Pegylation Cyclophilin Fungal Infection Fungal Infections

Is SCYX a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 3.07
52 Week Low 1.26
Average Volume 147,695
200-Day Moving Average 1.77
50-Day Moving Average 1.47
20-Day Moving Average 1.47
10-Day Moving Average 1.43
Average True Range 0.08
RSI (14) 36.31
ADX 24.32
+DI 8.82
-DI 21.78
Chandelier Exit (Long, 3 ATRs) 1.38
Chandelier Exit (Short, 3 ATRs) 1.57
Upper Bollinger Bands 1.61
Lower Bollinger Band 1.34
Percent B (%b) -0.01
BandWidth 18.30
MACD Line -0.04
MACD Signal Line -0.02
MACD Histogram -0.0162
Fundamentals Value
Market Cap 49.67 Million
Num Shares 37.2 Million
EPS 1.49
Price-to-Earnings (P/E) Ratio 0.90
Price-to-Sales 0.52
Price-to-Book 0.78
PEG Ratio 0.00
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 1.41
Resistance 3 (R3) 1.42 1.40 1.40
Resistance 2 (R2) 1.40 1.38 1.40 1.39
Resistance 1 (R1) 1.37 1.37 1.36 1.36 1.39
Pivot Point 1.35 1.35 1.34 1.35 1.35
Support 1 (S1) 1.32 1.33 1.31 1.31 1.28
Support 2 (S2) 1.30 1.32 1.30 1.28
Support 3 (S3) 1.27 1.30 1.27
Support 4 (S4) 1.26